Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials

Original Paper



To assess the efficacy and toxicity of the addition of estramustine to docetaxel-based chemotherapy for the treatment of castration-resistant prostate cancer.


We systematically searched, without language restrictions, for randomized clinical trials that compared docetaxel-based chemotherapy with or without estramustine in patients with histologically proven prostate cancer. The primary end point was overall survival (OS). Secondary endpoints were prostate-specific antigen (PSA) response rate and grade 3 or 4 toxicity. Data was extracted from the studies by 2 independent reviewers. The meta-analysis was performed by Stata version 10.0 software (Stata Corporation, College Station, Texas, USA).


Four randomized clinical trials (totally 400 patients) were eligible. Meta-analysis showed that there was significant improvement in PSA response rate in docetaxel-based therapy with estramustine group, compared with docetaxel-based therapy group (OR = 1.55, 95% CI = 1.10–2.18, P = 0.012). With regard to OS (HR = 0.873, 95% CI = 0.55–1.40, P = 0.572), grade3 or 4 neutropenia (OR = 1.27, 95% CI = 0.61–2.7), anemia (OR = 1.04, 95% CI = 0.07–16.3), thrombocytopenia (OR = 0.87, 95% CI = 0.13–5.7), diarrhea (OR = 2.3, 95% CI = 0.36–14.9), nausea (OR = 1.14, 95% CI = 0.16–8.35), mucositis (OR = 1.66, 95% CI = 0.50–5.52) , and vomiting (OR = 1.53, 95% CI = 0.23–10.3), and there were no significant differences between the two groups.


This was the first meta-analysis of docetaxel-based therapy with estramustine versus docetaxel-based chemotherapy in the treatment of castration-resistant prostate cancer. Our meta-analysis did not support the addition of estramustine to docetaxel-based chemotherapy for the treatment of castration- resistant prostate cancer, based on no gain in survival.


Docetaxel Estramustine Castration-resistant prostate cancer Meta-analysis 


  1. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRefGoogle Scholar
  2. Berry DL, Moinpour CM, Jiang CS et al (2006) Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24:2828–2835PubMedCrossRefGoogle Scholar
  3. Caffo O, Sava T, Comploj E et al (2008) Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 102:1080–1085PubMedCrossRefGoogle Scholar
  4. Eymard JC, Priou F, Zannetti A et al (2007) Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 18:1064–1070PubMedCrossRefGoogle Scholar
  5. Fizazi K, Le Maitre A, Hudes G et al (2007) Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: A meta-analysis of individual patient data. Lancet Oncol 8:994–1000PubMedCrossRefGoogle Scholar
  6. Gunnarsson PO, Forshell GP (1984) Clinical pharmacokinetics of estramustine phosphate. Urology 23(6 Suppl):22–27PubMedCrossRefGoogle Scholar
  7. Hahn NM, Marsh S, Fisher W et al (2006) Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 12:6094–6099PubMedCrossRefGoogle Scholar
  8. Hamilton A, Muggia F (2001) Estramustine potentiates taxane in prostate and refractory breast cancers. Oncology 15(5 Suppl 7):40–43PubMedGoogle Scholar
  9. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225–249PubMedCrossRefGoogle Scholar
  10. Machiels JP, Mazzeo F, Clausse M et al (2008) Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 26:5261–5268PubMedCrossRefGoogle Scholar
  11. Oudard S, Legrier ME, Boye K et al (2003) Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 169:1729–1734PubMedCrossRefGoogle Scholar
  12. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRefGoogle Scholar
  13. Perry CM, McTavish D (1995) Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7:49–74PubMedCrossRefGoogle Scholar
  14. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520PubMedCrossRefGoogle Scholar
  15. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRefGoogle Scholar
  16. Williams JF, Muenchen HJ, Kamradt JM et al (2000) Treatment of androgen-independent prostate cancer using anti-microtubule agents docetaxel and estramustine in combination: an experimental study. Prostate 44:275–278PubMedCrossRefGoogle Scholar
  17. Yusuf S, Peto R, Jones DR et al (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335–371PubMedCrossRefGoogle Scholar
  18. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28:123–137PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Oncology, The Sixth People HospitalShanghai Jiao Tong UniversityShanghaiChina

Personalised recommendations